A. Mandoli

发表

Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells

Matthew T. Maurano, Warren A. Cheung, Klaudia Walter, 2016, Cell.

Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes

S. Heath, P. Flicek, A. Merkel, 2019, Cell reports.

ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.

H. Stunnenberg, J. Martens, L. Altucci, 2012, Blood.

Allelic Landscape of Human Blood Cell Trait Variation and Links

William J. Astle, James R. Staley, J. Danesh, 2016 .

A Series of Ferrocene-Containing Pyrazolo[1,5-a]pyrimidines Induce a Strong Antiproliferative Effect against Oral Cancer Cells

A. Mandoli, Amit Shard, R. Rathod, 2022, Organometallics.

MLL-AF 9 and MLL-AF 4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX 1 program in 11 q 23 acute myeloid leukemia

A. Mandoli, Shuang-Yin Wang, T. Kuznetsova, 2017 .

CBFb-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia

J. Martens, E. Macintyre, N. Dillon, 2020 .

CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1

M. Vermeulen, J. Martens, P. Jansen, 2018, Blood Cancer Journal.

Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity

R. Xavier, L. Joosten, C. Wijmenga, 2014, Science.

MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia

A. Mandoli, Shuang-Yin Wang, B. A. van der Reijden, 2017, Oncogene.

Supplementary Fig. 1

Y. Ruan, H. Stunnenberg, J. Martens, 2021 .

E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer

P. V. van Diest, H. Stunnenberg, J. Martens, 2018, Scientific Reports.

GFI1 is required for RUNX1/ETO positive acute myeloid leukemia

J. Martens, T. Möröy, J. Schütte, 2018, Haematologica.

CBFB–MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia

M. Vermeulen, E. Vellenga, P. Jansen, 2013, Leukemia.

AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis

J. Martens, M. Laakso, A. Mandoli, 2016, Oncotarget.

The oncofusion protein FUS–ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia

J. Martens, A. Mandoli, K. Prange, 2015, Oncogene.

CBFβ-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia.

J. Martens, E. Macintyre, N. Dillon, 2020, Cell reports.

Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics.

K. Kalia, A. Mandoli, S. Behera, 2021, Oral oncology.

Deciphering the phenotypic heterogeneity and drug response in cancer cells using genome-wide activity and interaction of chromatin domains

Vibhor Kumar, R. Dasgupta, Shreya Mishra, 2023, bioRxiv.

Stem cells in molecular and regenerative medicine

A. Mandoli, 2012 .

Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392.

H. Stunnenberg, J. Martens, L. Altucci, 2014, Cancer Research.

Combined HAT/EZH2 modulation leads to cancer-selective cell death

S. Heath, P. Flicek, E. Novellino, 2018, Oncotarget.

CBFβ-SMMHC regulates ribosomal gene transcription and alters ribosome biogenesis

J. Martens, E. Macintyre, S. Fumagalli, 2017, Leukemia.

The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model

J. Martens, F. Ferrari, E. Janssen-Megens, 2019, PloS one.

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.

W. Hiddemann, K. Döhner, H. Döhner, 2016, Cell reports.

MEIS 2 Is an Oncogenic Pa rtner in AML 1-ETO-Positive AML Graphical

W. Hiddemann, K. Döhner, H. Döhner, 2022 .

CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia

H. Stunnenberg, M. Vermeulen, J. Martens, 2013 .

Role of epigenetics in OSCC: an understanding above genetics

A. Mandoli, Ambika Chamoli, V. Upadhyay, 2023, Medical Oncology.

Increased H3K9 methylation and impaired expression of Protocadherins are associated with the cognitive dysfunctions of the Kleefstra syndrome

Y. Hérault, H. Meziane, H. Stunnenberg, 2018, Nucleic acids research.

The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.

René A. M. Dirks, H. Stunnenberg, J. Martens, 2016, Cell reports.

Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment Microbiome in Cancer Therapy.

A. Mandoli, Anil B. Jindal, P. Dwivedi, 2022, Current drug targets.

Glucocorticoid receptor and nuclear factor kappa-b affect three-dimensional chromatin organization

Y. Ruan, H. Stunnenberg, J. Martens, 2015, Genome Biology.

Glucocorticoid receptor and nuclear factor kappa-b affect three-dimensional chromatin organization

Y. Ruan, H. Stunnenberg, J. Martens, 2015, Genome biology.

Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia

S. Heath, H. Stunnenberg, I. Gut, 2018, Oncotarget.

Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity

R. Xavier, L. Joosten, C. Wijmenga, 2014, Science.

The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease

James R. Staley, Klaudia Walter, R. Guigó, 2016, Cell.

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.

W. Hiddemann, K. Döhner, H. Döhner, 2016, Cell reports.

Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392.

H. Stunnenberg, J. Martens, L. Altucci, 2014, Cancer research.